These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39239161)

  • 1. Loss to follow-up among adults with drug-resistant TB in Papua New Guinea.
    Charles F; Lin YD; Greig J; Gurra S; Morikawa R; Graham SM; Maha A
    Public Health Action; 2024 Sep; 14(3):85-90. PubMed ID: 39239161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of bedaquiline containing all oral longer regimens in treating multidrug/rifampicin resistant tuberculosis in Pakistan.
    Khan A; Khan AH; Ahmad N; Ghafoor A
    J Infect Public Health; 2024 Sep; 17(9):102522. PubMed ID: 39173557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan.
    Makhmudova M; Maxsumova Z; Rajabzoda A; Makhmadov A; van den Hof S; Mirtskhulava V
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):331-336. PubMed ID: 30871664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
    Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
    PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
    Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
    BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Loss to follow-up in patients treated for multidrug-resistant tuberculosis in EcuadorA Perda de seguimento de pacientes tratados para tuberculose multirresistente a medicamentos no Equador].
    Tatés-Ortega N; Álvarez J; López L; Mendoza-Ticona A; Alarcón-Arrascue E
    Rev Panam Salud Publica; 2019; 43():e91. PubMed ID: 31892925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment after loss to follow-up reduces mortality in patients with multidrug/rifampicin-resistant tuberculosis.
    Choi H; Mok J; Ae Kang Y; Jeong D; Kang HY; Kim HJ; Kim HS; Jeon D
    ERJ Open Res; 2023 Jul; 9(4):. PubMed ID: 37583964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Profile of Multidrug Tuberculosis Regimen and Treatment Outcomes in Pulmonary MDR-TB Patients at the Tertiary Referral Hospital Dr. Soetomo, East Java, Indonesia: A Seven-Year Retrospective Study on Bedaquiline.
    Setyawan MF; Mertaniasih NM; Soedarsono S
    Acta Med Indones; 2023 Oct; 55(4):430-439. PubMed ID: 38213049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Takarinda KC; Thekkur P; Sandy C; Mharakurwa S; Makoni T; Ncube R; Charambira K; Zishiri C; Ngwenya M; Nyathi S; Chiteka A; Chikaka E; Mutero-Munyati S
    PLoS One; 2020; 15(4):e0230848. PubMed ID: 32353043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features, Adverse Events and Treatment Outcomes of Multidrug/Rifampicin-resistant Tuberculosis in Children and Adolescents: An Eight-year Retrospective Cohort Study in Bandung, Indonesia.
    Nataprawira HM; Gafar F; Sari CA; Alffenaar JC; Marais BJ; Ruslami R; Menzies D
    Pediatr Infect Dis J; 2024 Sep; ():. PubMed ID: 39312636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid mono-resistant tuberculosis: Time to take it seriously.
    Garg K; Saini V; Dhillon R; Agarwal P
    Indian J Tuberc; 2019 Apr; 66(2):247-252. PubMed ID: 31151492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014-2017.
    Khachatryan L; Grigoryan R; Dadu A; Kumar AMV; Akopyan K; Dumchev K; Harutyunyan H; Matteelli A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
    Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Social and health factors associated with adverse treatment outcomes among people with multidrug-resistant tuberculosis in Sierra Leone: a national, retrospective cohort study.
    Kamara RF; Saunders MJ; Sahr F; Losa-Garcia JE; Foray L; Davies G; Wingfield T
    Lancet Glob Health; 2022 Apr; 10(4):e543-e554. PubMed ID: 35303463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Factors Associated with Unfavorable Outcomes among Drug-Resistant TB Patients: A 6-Year Retrospective Study from Pakistan.
    Khan FU; Rehman AU; Khan FU; Hayat K; Khan A; Ahmad N; Chang J; Malik UR; Fang Y
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events using shorter MDR-TB regimens: outcomes from Port Moresby, Papua New Guinea.
    Mason CY; Prieto A; Bogati H; Sannino L; Akai N; Marquardt T
    Public Health Action; 2021 Mar; 11(1):2-4. PubMed ID: 33777714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
    Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
    BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT.
    Gao J; Gao M; Du J; Pang Y; Mao G; Lounis N; Bakare N; Jiang Y; Zhan Y; Liu Y; Li L;
    Trials; 2024 Apr; 25(1):227. PubMed ID: 38561815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia.
    Soeroto AY; Nurhayati RD; Purwiga A; Lestari BW; Pratiwi C; Santoso P; Kulsum ID; Suryadinata H; Ferdian F
    PLoS One; 2022; 17(1):e0263304. PubMed ID: 35089981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.